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APPETITE REGULATION BY LEPTIN 
MASON HIU-KWONG CHAN  
ABSTRACT 
 Obesity is a prevalent problem in modern society, which requires the upmost 
attention in the biomedical sciences. A leading cause of obesity related diseases is due to 
overeating, especially in industrialized countries. Leptin is the hormone that is secreted 
by fat cells responsible for communicating body nutritional status to the brain. Leptin 
interacts with other bodily systems such as the cognitive, digestive, neuronal, and 
endocrine systems. Leptin acts mainly on the Ob-Rb receptor in the arcuate nucleus of 
the hypothalamus and largely suppresses food intake and increases energy expenditure by 
activating Proopiomelanocortin and Cocaine- and amphetamine-regulated transcript 
(anorexigenic signals) neurons and by suppressing Neuropeptide Y and Agouti-related 
peptide (orexigenic signals) neurons, among other chemical signaling pathways. In both 
rodent and human studies, exogenous leptin administration resulted in elevated plasma 
leptin concentrations. When researchers tried to use leptin for weight reducing medical 
treatments in humans, the results show difficulty in establishing clinical efficacy. 
However, for diseases such as congenital leptin deficiency, obesity related leptin 
resistance, and lipodystrophy, medical treatments involving exogenous leptin have been 
relatively successful. The goal of this thesis is to give readers an understanding of leptin’s 
role in regulating appetite and the different leptin associated diseases. Leptin’s role is still 
continuing to be developed and more research is needed to fully utilize leptin for 
therapeutic benefit.   
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INTRODUCTION 
Obesity  
 
Obesity is a relatively recent global epidemic of huge public health concern. As of 
2011-2012, an estimated 1.46 billion adults and 170 million children worldwide were 
classified as obese; in the United Sates, as many as 1 in 3 adults and 1 in 5 children are 
classified as obese (Ogden et al., 2014; Finucane et al., 2011). In 2014, the World Health 
Organization estimated that there were approximately 2 billion people over the age of 18 
(adults) that were classified as overweight (as defined by Body Mass Index of 25.0-29.9) 
with around a third of these people classified as obese (as defined by BMI > 30 kg/m2) 
(McAinch, 2016). These recent figures represent a doubling of obesity rates and 
occurrence when compared to epidemiological data from the 1980s. These ongoing 
trends create a sense of urgency in trying to understand and find a way to control this 
global epidemic.  
These increasing rates of obesity can be explained by two reasons: the rampant 
overconsumption of high fat composition meals and the decrease in physical activity 
(Jéquier, 2002). The rise of commercialization and industrialization have produced 
processed food choices that are equally unhealthy and filled with unnecessary calories. In 
addition, due to technological advancements in society, humans no longer are required to 
perform strenuous and energy expenditure labor to fulfill basic needs. There are also 
noticeable trends regarding gender differences in obesity; obesity is more common in 
females, as a survey of adults in the United States in 2013-2014 found that the prevalence 
of obesity in men was 35% and in women was 40.4% (Flegal et al., 2016). 
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The Body Mass Index (BMI) is determined by the weight relative to the height, 
calculated as a ratio between these two (formula= weight (kg)/height2 (meters)). The 
ideal BMI measurement is the level at which life expectancy is expected to be maximal 
and a BMI of greater than 28 is considered to represent obesity, with the associated high 
risk of diabetes, hypertension, and heart disease, all whose incidences increase with 
increasing BMI (Harris et al., 1988). In addition, total life expectancy is reduced when 
BMI is 20% or more above the set ideal.  The BMI is a direct indicator of estimated 
adiposity and can be used quickly by health professionals when classifying the degree of 
obesity in the individual. 
  Human energy expenditure has been calculated to average around 2567 kcal/day 
in normal weight subjects and 3033 kcal/day in obese subjects (Elbelt et al., 2010).  
These differences are due to the fact that obese subjects tend to physiologically burn 
more calories per time unit due to the extra mass that person has to carry around all the 
time. A common measurement for energy expenditure as relating to basic physiological 
needs is measured by the basal metabolic rate (BMR).  The BMR is the largest 
contributor of total energy expense and affects the overall energy balance of the 
individual (Sabounchi et al., 2013).  Components of BMR estimation equations take into 
account the different factors: gender, height, BMI, weight, age, race, fat-free mass, ratio 
of hip to waist, and fat mass. This passive energy expenditure plays a large role in 
controlling human appetite as it represents the bare minimum energy needed for basic 
metabolic processes. 
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Human Appetite 
The act of eating is a primal satiable desire that needs to be controlled and 
regulated both at local and central centers and influences our behavior: whether we feel 
hungry or full. Human appetite is a complicated motivated behavior that is controlled by 
many factors that include physiological, cognitive, digestive, endocrine, and neuronal 
components (Mourao et al., 2007). This combination of factors allows the human body to 
access different nutritional needs and act accordingly in response, whether to stimulate or 
inhibit the feeling of hunger. The interconnected nature of these connections implies that 
there are multiple levels of regulation through hormones and bodily signals. Moreover in 
adults, nonfood-related factors such as reduced physical activity, smoking, alcohol 
consumption, mental illnesses, and a low socioeconomic status all have negative impacts 
on body weight, and hence, largely contribute to abnormal human appetite behavior 
(Anderson et al., 2016). Knowing that the control of human appetite cannot be simply 
defined by internal factors is of importance when trying to understand feeding behavior. 
Regulated human appetite behavior can also be separated into homeostatic, which 
are based on energy deficits or of particular nutrients and non-homeostatic factors, which 
are based on environmental constraints, palatability, opportunity, and social situation 
(Woods et al., 2015). Other subtle food related environmental cues such as the packaging, 
variety, portion size, food’s salience, and palatability have some control on how much we 
consume (Deborah A. Cohen & Babey, 2012). In addition, increases in money spent by 
the food industry on food advertising creates food cues that encourage people to always 
feel the need to eat, even thought they may physiologically be nourished, a problem 
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leading to troublesome, inadvertent weight gain (D. A. Cohen, 2008). Feeding behavior is 
thought to be based more on habits rather than conscious rational decisions, as feeding 
habits are established and motivated by prior experiences (Marteau et al., 2012; Rangel, 
2013). These external factors add to the problem of determining the physiological need of 
hunger (e.g. hormones and nutritional pathways). 
Especially in rich, industrialized countries where access to food is not of concern, 
the consumption of highly palatable energy-dense foods is characterized as hedonic 
eating (Zheng et al., 2008). This is contrasted with poor, underdeveloped countries where 
food access is limited and human appetite behavior is more concerned with just fulfilling 
basic nutritional needs to survive. Understanding the connection between a country’s 
economic status, as can be easily determined by Gross Domestic Product and average 
household income, and its citizen’s eating habits is helpful in understanding the 
epidemiology of appetite-related diseases such as obesity. These observations can also 
shed light as to why obesity is more prevalent and of greater public health concern in 
wealthy, industrialized countries.  
Other causes of changes to appetite behavior can be due to the widespread use of 
new endocrine system-disrupting chemicals: chemicals that influence epigenetic 
mechanisms to promote obesity, the growing use of antibiotics in children, and the spread 
of medications that encourage weight gain (McAllister et al., 2009). These medical 
interventions drastically alter behavior, therefore becoming etiological factors that 
knowingly contribute to the obesity epidemic. With every treatment targeting obesity, 
health professionals need to be careful in monitoring the possible side effects that affect 
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other body systems, as the appetite system is well interconnected and readily impacts 
other systems.  
 The gastrointestinal system is the focal point when talking about the regulation of 
appetite, as it is the general site of digestion and absorption of food. Physiologically, the 
endocrine and exocrine glands of the gastrointestinal system, composed of organs like the 
pancreas, liver, and major salivary glands are protein-synthesizing and protein-secreting 
systems that are natural components of controlling feeding behavior through their 
regulated secretions (Goldfine et al., 1997).  Exocrine glands are known to utilize the 
duct system to secrete their products into the lumen of the GI tract; whereas, endocrine 
glands internally release their products, through the interstitial system into the blood 
stream (Isenman et al., 1999).  The gastrointestinal system also controls locally how 
much food is needed and therefore leads to the immediate inhibition of hunger. These 
two systems work together to accomplish the goal of mechanically and chemically 
breaking down food into usable energy sources. 
 
Glucose 
 Glucose in an important sugar that is the basic source of human energy; two 
hormones that control the amount of glucose in the body are insulin and glucagon 
(Aronoff et al., 2004) . The roles of these hormones are often discussed in the context of 
human appetite and obesity and diabetes.  Type I diabetic patients do not produce insulin 
and therefore have high plasma concentrations of glucose. In humans, plasma glucose is 
regulated to stay in the range of 4-7 mM and is kept in homeostasis by balancing glucose 
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absorption from the intestine, metabolism by peripheral tissues, and production by the 
liver (Saltiel et al., 2001). The nutrient, glucose, is an essential power source for cellular 
respiration and supplies a portion of the cell’s nutritional needs. Glucose and insulin have 
important biological functions and their pathways interact. 
The pancreas’ islets of Langerhans, which have the beta cells, respond with an 
increase in insulin within seconds of detecting a significant rise in blood glucose levels 
(Grodsky et al., 1967). Two glucose phosphorylating enzymes on the beta cells have 
different affinities for the glucose substrate, which allow the pancreas to release glucose 
from glucose-6-phosphate into the plasma to correlate with blood glucose levels 
(Matschinsky et al., 1968).  This immediate response allows the pancreas to have control 
over plasma glucose concentrations. Insulin has the ability to stimulate processes related 
to cell growth and promotes storage of substances in adipose, liver, and muscle tissue by 
stimulating glycogen, protein synthesis, lipogenesis, and inhibiting glycogenolysis, 
breakdown of protein, and lipolysis (Mitrakou et al., 1991).  
 Conversely, the alpha cells of the islet of Langerhans produce glucagon, which 
contributes to maintaining glucose homeostasis through the modulation of glycogenolysis 
and gluconeogenesis (Jiang et al., 2003) . Glucagon is a catabolic (breakdown) hormone 
that directly opposes the effect of insulin. It controls blood glucose level by stimulating 
the conversion of stored glycogen to glucose in the liver, and therefore increasing plasma 
glucose concentrations. Together, the roles of pancreatic glucagon and insulin are 
highlighted and summarized in Table 1. 
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Table 1- Effects of Glucoregulatory Hormones. Adapted from (Aronoff et al., 2004). 
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Discovery of Leptin 
 
Leptin is the product of the obese (ob) gene and is a hormone synthesized directly 
by adipocytes that signals applicable energy reserves directly to the brain.  Leptin 
influences developmental, growth, metabolism, and reproduction processes (Denver et 
al., 2011). In the years 1950 to 1965, researchers discovered two genes designated obese 
(ob/ob) and diabetic (db/db) in two separate mouse strains at the Jackson Laboratory 
(Ingalls et al., 1950; Hummel et al., 1966). These mice had identical phenotypes of 
insulin resistance, morbid obesity, lethargy, and infertility.  The ob/ob gene product was 
found to be missing a blood-borne factor, leptin, while the db/db gene product was 
observed to be missing the receptor for this particular factor, the leptin receptor. Coleman 
further studied the ob and db genes in detail; ob/ob and db/db mice both have identical 
phenotypes, with both weighing three times as much as controls and both exhibiting a 
five times higher body fat content, compared to controls (Coleman, 1978). Forty years 
later, Jeffrey Friedman’s group discovered the ob or Lep gene encodes leptin and named 
it after the Greek word ‘leptos’, which means thin (Zhang et al., 1994).  Leptin was the 
first adipokine (an adipose tissue hormone) to be discovered. One year later, Tartaglia et 
al. reported the isolation of the leptin receptor gene (Tartaglia et al., 1995).  
The mouse leptin gene size is 4.5 kilobase long with a conserved 167 amino acid 
open reading frame region (Zhang et al., 1994).  Regulation of the leptin gene promoter, 
which controls leptin production, occurs through cyclic AMP, glucocorticoid response 
elements, Sp1 binding sites, and CCATT enhancers (Gong et al., 1996). Genetic analysis 
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of the leptin gene product showed that human leptin is 83% identical to rat leptin and 
84% identical to mouse leptin (Ahima et al., 2000); this relatively close similarity means 
that researchers can use mouse and rat models to predict human effects. In addition, it 
was found that there is a positive correlation between leptin mRNA levels in adipose 
tissue and plasma leptin concentrations (Maffei et al., 1995). Hence, more leptin mRNA 
meant higher plasma leptin concentrations.  
Ob/ob mice are used to study the general effects of leptin deficiency. Leptin 
deficient ob/ob mice are known to have neuroendocrine abnormalities similar to mice that 
are starving. In leptin deficient obese humans and rodents, exogenous leptin 
administration leads to neuroendocrine normalization and decreases in food intake, 
consequently reversing obesity (Zhang et al., 2005). Mutations of the ob gene results in 
extreme obesity and leptin resistance in mice, that is similar to the morbid obesity 
phenotype seen among humans (Zhang et al., 1994). Ob/ob mouse are generally 
classified as morbidly obese, hypothermic, hyperphagic, and have neuroendocrine 
abnormalities (Lutz et al., 2012). During periods of starvation, the main physiological 
role of leptin is to regulate the neuroendocrine system. There is a compounding problem 
with obesity: leptin levels rise with increasing adiposity (Ahima et al., 1996).  
The crystal structure of human leptin, a 16 kilo Dalton protein produced from a 
gene on Chromosome 7, has been elucidated and found to contain 4 α helix bundle folds, 
which closely resemble other class I helical cytokines (Huising et al., 2006). The most 
highly conserved amino acid stretch is GLDFIP (positions 38-43 in human leptin 
protein), and mutations of amino acids LFI to alanines generates an antagonist that fails 
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to activate the leptin receptor.  Overall, there is a considerable difference in primary 
amino acid sequence among different vertebrates, however their secondary, tertiary, and 
quaternary structures are evolutionally conserved across species (Peelman et al., 2006).  
This preservation throughout evolution suggests that leptin has an essential role in the 
control of appetite and in the primal need to eat in vertebrates. 
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General Effects of Leptin 
 
Leptin has the ability to induce the storage of triglycerides in adipose tissue and 
has control over human appetite (Friedman et al., 1998). There are two influential time 
frames for the actions of leptin: over the short term, increased plasma leptin levels send a 
satiety signal, and over the long term, daily increased plasma leptin concentrations send 
information about long-term energy status to the brain. Paradoxically, obese individuals 
have high levels of circulating leptin, suggesting that leptin resistance plays a significant 
role in obesity (Caro et al., 1996).  
Circulating leptin levels, produced by adipocytes, act at the hypothalamic central 
level to decrease food intake and increase consumption of energy when the body is well 
nourished. Since leptin is structurally related to the type I cytokine superfamily, it acts 
through the modulation of cell signaling and is important in the overall immune response. 
Leptin regulates the function of other immune cells: neutrophils, dendritic cells, natural 
killer cells, macrophages, basophils, eosinophils, and macrophages (Al-Suhaimi et al., 
2013)  Together, these effects stimulate pro-inflammatory responses, and hence, regulate 
a component of autoimmune/inflammatory diseases (Procaccini et al., 2016). 
Ingestion of food during a meal leads to hunger inhibition that results in the 
subsequent termination of eating (Jéquier, 2002). This feedback involves mechanisms 
that prevent overeating and is called satiation. The satiation period is followed by the 
absence of hunger: satiety. The resurgence of hunger occurs when the period of satiety is 
terminated; and this cycle repeats. Researchers found that because stimulation of leptin 
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secretion is not associated with the rise in serum insulin concentrations after a meal, 
leptin cannot be classified as either a satiation or a satiety factor in humans since small 
changes in food intake do not increase plasma leptin concentrations (Considine et al., 
1996). This is in conflict with Caro et al.’s conclusions that leptin acts as a satiety signal.  
These conflicting conclusions may be explained by the fact that Considine, et al. consider 
that high insulin levels signal that a subject is a full. According to these authors, leptin 
does not determine or influence immediate meal size.    
Leptin acts as a negative feedback control and as an “adipostatic signal” to the 
hypothalamus, which controls overall energy homeostasis (Maffei et al., 1995).  In this 
study with rodents and 87 obese and lean humans, plasma leptin concentrations were 
found to be highly correlated with body mass index (BMI). Food restriction led to a 
decrease in plasma leptin levels, which led to weight. Friedman and Halaas hypothesized 
that leptin is an afferent signal in a negative-feedback loop which controls the size of 
adipose tissues (Friedman et al., 1998). They believed that (1) adipocytes express leptin 
RNA, (2) leptin circulates in the plasma, (3) plasma leptin levels should correlate with the 
size of adipose tissue, and (4) recombinant leptin should reduce the body fat content 
when injected into ob/ob and wild-type mice, but not when injected into db/db mice. 
Leptin’s journey to its cellular targets can be seen in Figure 1 (Friedman et al., 1998) 
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Figure 1- Leptin and Adipose Tissue Mass. Leptin’s main action is on the hypothalamus. 
Leptin has some peripheral effects on T cells, pancreatic beta cells, and circumventricular 
organ, but these actions account little for leptin’s general effect through the 
hypothalamus. Adapted from (Friedman et al., 1998). 
 
 
Leptin also impacts the hypothalamic neuropeptide signaling circuitry by linking 
the negative-feedback regulation of appetite with body weight (Inui, 1999).  This system 
is based on the neuropeptide Y orexigenic network, a signaling cascade that works in 
conjunction with feeding-inhibitory neuropeptides like glucagon-like peptide 1(GLP-1), 
corticotropin-releasing factor and melanocortin.  This orexigenic network is appetite 
stimulant and increases food consumption. Leptin is an anorexigenic hormone, an 
appetite-inhibiting signal; it is through antagonizing the orexigenic pathway that leptin 
has an ability to limit body adiposity.  
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Synthesis and Release of Leptin 
 
The major locations of leptin mRNA expression are in the stomach, adipose tissue 
and liver (Friedman, 1998).  The leptin mRNA is also expressed at minor levels in the 
heart, placenta, fetal tissue, pituitary gland, and brain. Table 2 shows the factors that 
increase or decrease leptin concentrations in different tissues (Ahima et al., 2000). 
 
Table 2- Regulation of Leptin Expression. Adapted from (Ahima et al., 2000).
 
 
 
The amount of leptin synthesized is generally determined by the degree of 
adiposity. More leptin gene is expressed in bigger adipocytes than in smaller adipocytes 
and the amount of leptin secreted is strongly correlated with fat cell volume (Lönnqvist et 
al., 1997). The mechanical stretch of the fat cell, as determined by the stored amount of 
triglyceride, might produce signals to increase leptin synthesis (Caro et al., 1996). 
Researchers have also found that hexosamine and UDP-N-acetylgucosamine (UDP-
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GlcNAc) act as potential links between cell size and the amount of leptin released in 
humans (Considine et al., 2000). BMI is positively correlated with the amount of UDP-
GlcNAc in human subcutaneous adipose tissue.  Furthermore, UDP-GlcNAc synthesis is 
positively correlated with leptin release, while inhibition of the hexosamine biosynthesis 
pathway lowers leptin production. UDP-GlcNAc provides a signal to the body of 
adipocyte size that controls leptin synthesis.  
The composition of a meal is a determinant of circulating leptin concentrations in 
humans; for example, a low fat/high carbohydrate meal increases circulating leptin 
concentrations, compared with a high fat/low carbohydrate meal (Havel et al., 1999). Meals 
with high fat compositions, relative to high carbohydrate meals, decreases 24-hours 
circulating plasma leptin levels after a meal (Havel, 2000). Protein composition in a meal 
does not influence leptin production (Heini et al., 1998). Most importantly, the meal 
composition, not the meal size, affects leptin production. In rodents, meals rich in n-6 
polyunsaturated fatty acids (PUFAs) increased leptin production but meals rich in n-3 
PUFAs did not (Takahashi et al., 2000). In contrast, leptin concentrations fell when human 
subjects were fed meals rich in n-3 PUFAs but levels stayed the same when subjects were 
fed n-6 PUFAs rich meals (Reseland et al., 2001). This discrepancy is startling as it shows 
a differing relationship between rodent and human PUFAs concentrations and leptin 
production. This example highlights the fact that even though mouse models do not always 
correlate with pathways in humans. 
 As previously discussed, there are gender differences in the production of leptin.  
Serum leptin concentrations are significantly lower in men than in women. One 
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prevailing explanation is that women have significantly larger subcutaneous adipose 
tissue mass (general fat under the skin) relative to omental adipose mass (fat in the lower 
abdominal area) than men (Rosenbaum & Leibel, 1999). A secondary contributing factor 
is that reproductive hormones heavily impact leptin production. Androgenic hormones, 
which are usually related to male reproductive health, inhibit leptin synthesis and 
estrogens, which are usually related to female reproductive health, stimulate leptin 
synthesis (Jockenhövel et al., 1997).  These established gender differences should be 
accounted for when considering leptin treatment options and the role that leptin has on 
obesity in different sexes. 
Circadian rhythms also play an important part in the daily regulation of plasma 
leptin levels (Licinio et al., 1998). Leptin concentrations are maximal at nighttime.  Lean 
subjects and men have higher relative diurnal amplitudes; in addition, the diurnal amplitude 
decreases with increasing age.  The ultradian rhythm, which have repeating cycles shorter 
than 24 hours, of leptin secretion’s periodicity is similar in men and women (Saad et al., 
1998). However, pulse frequency is decreased in obese subjects. Pulse amplitude is lower 
in men than in women and positively correlates with BMI. These trends are interesting and 
might explain why we feel hungrier and eat more during the day. Chronic sleep deprivation 
reduces plasma leptin concentrations, since an increase in melatonin concentrations, which 
cause sleep, causes a decrease in plasma leptin (Knutson et al., 2007).  
 Researchers have elucidated three regulatory steps for leptin production: (1) a 
sensor that observes the size of the adipose tissue mass, (2) hypothalamic control centers 
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that consolidate the leptin signal from different sources, (3) effector systems that control 
energy intake and energy expenditure (Jéquier, 2002).  
Leptin binds to the leptin receptor and activates mainly the Janus kinase (JAK) 
signal transducer of transcription 3 (STAT3) signal transduction pathway (Triantafyllou et 
al., 2016). Some other pathways that are activated are the phosphatidylinositol 3 kinase 
(regulation of glucose homeostasis), mitogen-activated protein kinases/extracellular 
signal-regulated kinases pathway (fatty acid synthesis regulation), 5’-adenosine 
monophosphate-activated protein kinase (potential coregulator pathway of pancreatic beta-
cell functions and insulin secretion), and mammalian target of rapamycin (pathway that 
promotes intestinal cell proliferation) (Park et al., 2014).  Leptin’s primary signals target 
the hypothalamus, which is the central brain organ for maintaining homeostasis and 
controlling hunger.  
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Factors that Modulate the Release of Leptin 
 
Insulin and Glucocorticoids 
Insulin lowers blood glucose levels when levels are above normal; insulin also 
increases leptin promoter activity (Moreno-Aliaga et al., 2001). After incubating 
adipocytes with insulin for 1-2 hours, there was no observed increase in leptin mRNA 
levels, yet there was an observed increase in leptin release. These results suggest that 
insulin has control over leptin secretion through posttranscriptional mechanisms (Bradley 
et al., 1999).  
Glucocorticoids (GC) are long-term regulators of leptin expression (Russell et al., 
1998;Elimam et al., 1998). By acting on adipocytes, GC increase leptin mRNA levels; in 
vitro incubation of a synthetic GC in rat adipocytes increased leptin secretion (Bradley et 
al., 1999). Researchers also found that oral glucocorticoids increased leptin mRNA and 
serum leptin levels by two-folds, 24-48 hours after absorption (Laferrère et al., 2002). 
Furthermore, cell cultures incubated with a combination of GC and insulin have increased 
leptin mRNA levels synergistically, implying that these hormones work together and are 
major regulators of plasma leptin levels.   
 
Nervous System 
The regulation of leptin and TNFα (Tumor Necrosis Factor) may be 
interdependent and similar since they have comparable functions of reducing food intake, 
stimulating lipolysis, and suppressing lipid synthesis (Zhang et al., 2000).  Leptin limits 
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adipose tissue mass. TNF α has the dual role of stimulating preformed leptin secretion 
from mature human adipocytes and of inducing adipocyte differentiation.  TNF α 
treatment led to increased leptin levels in human subjects (Kirchgessner et al., 1997).  
This is an interesting relationship as it connects a cell signaling protein, a cytokine, to 
leptin production, whose protein structure resembles that of a cytokine. 
The immune system through the sympathetic nervous system has a dual function in 
regulating energy expenditure and adipose tissue lipolysis (Bartness et al., 1998).  White 
adipose tissue (WAT) is the predominant energy storage known as the “bad fat”; brown 
adipose tissue is the “good fat,” related to heat production. Increased sympathetic activity 
in WAT occurs in conditions associated with decreased leptin secretion and synthesis, such 
as during fasting and cold exposure.  Meanwhile, β-adrenoceptor and catecholamine 
agonists inhibit leptin production; this suppressive effect is mediated by β 3-adrenoceptor 
agonists which actively decrease circulating leptin concentrations (Hardie et al., 1996).  
Leptin also causes sympathetic nervous system activation, which in turns provides 
regulatory feedback inhibition over leptin release (Eikelis et al., 2003). In an experiment 
of leptin infusion in humans, researchers found similar support of this hypothesis, 
especially regarding renal sympathetic outflow, but the theory of regulatory feedback 
inhibition has yet to be confirmed. Intracerebroventricular injections of leptin increased 
metabolic rates through increased release of norepinephrine from sympathetic nerve 
terminals that innervate BAT (Mistry et al., 1997).  
Leptin stimulates the anorexigenic pathways and antagonizes the orexigenic 
pathways. Figure 2 illustrates the general effects of leptin action on the nervous system 
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through these pathways (Friedman et al., 1998). The orexigenic neuropeptides that are 
down-regulated by leptin are NPY (neuropeptide Y), orexins, MCH (melanin-
concentrating hormone), and AGRP (agouti-related peptide) (Jéquier, 2002). Meanwhile, 
the anorexigenic neuropeptides that are up regulated by leptin are alpha-MSH (alpha-
melanocyte-stimulating hormone), which acts on CART (cocaine and amphetamine-
regulated transcript), MC4R (melanocortin-4 receptor), and CRH (corticotrophin-releasing 
hormone). 
 
Figure 2- Anorexigenic and Orexigenic Effects of Leptin. Adapted from ( Friedman et al., 
1998) 
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Cellular Pathways Involved in the Actions of Leptin 
After a meal, amino acids levels and plasma insulin concentrations initiate the 
mTOR pathway, which stimulates leptin biosynthesis through mechanisms involving the 
5’ and 3’ UTR (Lee et al., 2009). Cyclic adenosine monophosphate activates (cAMP) 
epacs, which are exchange proteins that act downstream of cAMP and influence both 
energy balance and glucose homeostasis (Hu et al., 2016).  Deletion of the Epac 1 genes 
in mice led to an increase in sensitivity for leptin in the hypothalamus; Epac 1 also 
promotes leptin expression and secretion in WAT.   
Hexoses and lactates also increase leptin release; this generation of energy/ATP, 
plays a huge role in influencing leptin production (Mueller et al., 1998). Because leptin 
secretion requires ATP, inhibition of glucose uptake would inhibit leptin secretion. When 
energy stores are low, the body needs to eat to restore energy levels. The influx of 
glucose through the hexosamine biosynthetic pathway, a cellular “sensor” of energy 
stores, is communicated as adequate energy stores and stimulates leptin gene expression 
and secretion in both muscle and adipose tissue (Wang et al., 1998).  
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Cellular Targets of Leptin 
 
Leptin Receptor  
 All leptin receptors are in the glycoprotein 130 (gp130) family of cytokine receptors 
and have six isoforms, Leptin Receptor a-f, all of which are encoded by the LepR gene 
(Tartaglia et al.). Ob-Rb receptor is the predominant “longest” form, and mutations of this 
gene cause severe obesity, as leptin is unable to bind to its receptor.  Eleven pathogenic 
mutations of the leptin receptor, which affect the bioactivity, have been reported.  
 In Zucker fatty rats (fa/fa), another rat model used to observe obesity pathology, 
substitutions in OB-Rb result in reduced signaling capacity, leptin binding affinity, and cell 
surface expression (Silva et al., 1998). Obese fa/fa rats  have leptin resistance and are not 
particularly sensitive to leptin’s effects. Even though obese humans have high plasma 
leptin concentrations, because of leptin resistance, they do not see the actions of leptin (i.e., 
reduced food intake and increased energy expenditure) (Maffei et al., 1995).  
In gastric chief cells, leptin is released upon sensing secretin and gastrin and is 
actively inhibited by cholecystokinin.  Leptin receptors in the gastric epithelium are also 
of Ob-Rb form.  The role of leptin in the stomach is still unclear but seems to be in charge 
of the local regulation of appetite, and possibly through interacting with cholecystokinin, 
which inhibits hunger (Mix et al., 2000).  
Leptin binding to its receptor activates the JAK-STAT signaling pathway which 
induces cellular anti-apoptotic events, angiogenesis, and proliferation (Mullen et al., 2016). 
The gene product also interacts with notch and IL-1 (NILCO), which are involved with 
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promoting tumor growth.  Further research needs to be done to determine if there is a link 
between leptin signaling and cancer growth.  
 
Effects of Leptin on Growth and Reproduction 
Leptin receptors in hypothalamic nuclei release somatostatin, somatotropin release- 
inhibiting factor, and growth hormone releasing hormone and this suggests that leptin 
regulates growth hormone (GH) secretion. GH secretion is essentially tied to nutritional 
status as it stimulates growth, cell division, and cell repair in humans. Leptin infused i.c.v. 
for 7 days increased GHRH concentrations - stimulating GH secretion, (Tannenbaum et 
al., 1998; Carro et al., 1997). Food deprivation inhibits GH secretion and this was reversed 
by i.c.v. leptin injections in fasted rats. Leptin also interacts with the hypothalamic-
pituitary system as leptin stimulated LHRH release from hypothalamic cells and FSH and 
LH release from the anterior pituitaries of adult male rats (Yu et al., 1997). These results 
show that leptin has an important function in regulating gonadotropin concentrations.  
In female ob/ob mice that were not able to deliver viable young, leptin treatment 
restored fertility (Barash et al., 1996). During pregnancy, leptin travels to the fetal tissue 
from the placenta to the developing fetus where it is involved in angiogenesis and 
hematopoiesis (Reitman et al., 2001).  However, its precise role remains unclear and more 
research into leptin’s role in the fetus is necessary to determine its impact on the newborn. 
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Specific Actions of Leptin on the Brain 
 
The hypothalamus is the central brain region regulating appetite. This brain region 
is responsible for controlling the autonomic nervous system and homeostatic systems 
such as temperature, thirst, and hunger (Berthoud et al., 2007). Leptin receptors have 
been found in different hypothalamic nuclei: Paraventricular Nucleus of Hypothalamus 
(PVN), Ventromedial Nucleus of Hypothalamus (VMH), Dorsomedial Hypothalamus 
(DMH), Lateral Hypothalamus (LH), and the arcuate nucleus (ARC) (Mercer et al., 
1996). The LH modulates the activity of the parasympathetic nervous system, while the 
VMH modulates the activity of the sympathetic nervous systems; microinjections of 
leptin into the VMN reduced food intake (Jacob et al., 1997). The DMH inputs into the 
parasympathetic nervous system and integrate information among the other hypothalamic 
nuclei. The PVN projects with both sympathetic and parasympathetic efferents and 
controls secretion of peptides from both the posterior and anterior pituitary. Figure 3 
shows the body’s adaptation to starvation, through these pathways (Ahima et al., 2000).  
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Figure 3– Leptin Signaling and Adaptation to Starvation. Adapted from (Ahima et al., 
2000). 
 
 
NPY/AGRP and POMC/CART neurons are regulated by leptin by an opposite 
manner (Schwartz et al., 2000). NPY/AGRP neurons operate when leptin levels are low. 
Reduced insulin or leptin levels inhibit POMC and CART expression in the arcuate 
nucleus. Products of the POMC (proopiomelanocortin) gene affect feeding behavior as 
POMC neurons express leptin receptor mRNA and have a similar distribution of leptin 
mRNA in the arcuate nucleus (Cheung, Clifton, & Steiner, 1997). Other peptides that 
increase and decrease food intake are listed in Table 3 (Friedman et al., 1998). 
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Table 3- Hypothalamic Modulators of Food Intake. Adapted from (Friedman et al., 1998). 
 
Neuropeptide Y, a potent stimulator of feeding, is expressed in ARC hypothalamic 
neurons. NPY secretion in the PVN increases during periods of hunger and decreases after 
eating (Sahu et al., 1988).  NPY and OB-Rb mRNA are co-expressed in ARC neurons 
which are activated by fasting (Håkansson et al., 1996). NPY was found to not be the main 
regulator of leptin’s action, because knockout of the NPY gene in ob/ob mice did not fully 
reverse the obesity pathology, indicating that other neuropeptides also play an important 
role (Erickson et al., 1996). 
Weight loss correlating with WAT browning occurs when leptin and insulin act 
together on hypothalamic neurons (Dodd et al., 2015). Phosphatases regulate metabolism 
through the CNS (Banno et al., 2010). The deletion of the phosphatases PTP1B and TCPTP 
improved insulin and leptin signaling in POMC neurons and stopped DIO through 
increasing WAT browning. Leptin by itself promotes BAT activity; this coordination of 
available energy stores is done through leptin and insulin and is centered on the control of 
WAT browning. These results contribute to the “diet-induced thermogenesis” model of 
body weight control which involves BAT cellular differentiation and expansion in rodents 
(Rothwell et al., 1979).   
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 In obese patients, leptin transport across the BBB might be impaired, leading to 
leptin resistance (Schwartz et al., 1996). DIO mice generally retain sensitivity to centrally 
administered leptin and develop resistance to peripherally administered leptin (Van Heek 
et al., 1997). In humans, the ratio of leptin concentrations in the CSF and in the plasma are 
lower in obese individuals (Caro et al., 1996). Radioiodinated leptin 125I-leptin crosses the 
blood-brain barrier at a rate of 5.87 x 10-4 ml/g-min, a rate that is 20 times greater than 
labeled albumin (Banks et al., 1996). Leptin is transported intact by a short form of the 
leptin receptor (Ira) through the BBB by a saturable transporter-mediated system and the 
efficiency for leptin transport through the BBB is lower in obese individuals (Lee et al., 
1996).  
Growing evidence suggests that leptin positively influences neuroprotection, axon 
growth, synaptogenesis and neurogenesis (Paz-Filho, Wong, & Licinio, 2010). Lean 
individuals with high plasma leptin levels have lower risks for neurodegerative diseases 
such as dementia and Alzheimer’s disease, showing that leptin could be used to treat these 
disease (Lieb et al., 2009). With additional research, leptin could possibly be used to treat 
depression, anxiety, and improve overall cognition.   
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Specific Actions of Leptin on Glucose Metabolism 
 
General fasting decreases plasma leptin levels because of decreases in adipose 
glucose metabolism, whereas re-feeding increases adipose glucose metabolism which leads 
to higher plasma leptin levels (Mueller et al., 1998). Leptin in soleus muscle exerts its 
action similar to the effects of insulin: simulating glucose oxidation, lactate formation, 
glycogen synthesis, and glucose uptake (Ceddia et al., 1999). Rapid elevations in 
circulating leptin concentrations modulates liver gene expression of gluconeogenic enzyme 
phosphoenolpyruvate carboxykinase (PEPCK), which regulates the gluconeogenesis 
pathway (Frühbeck et al., n.d.). These and additional effects can be seen in Figure 4 
(Fernández-Formoso et al., 2015).   
 
Figure 4- Leptin’s effect on Glucose Homeostasis. Shown are the main actions performed 
by leptin in different tissues. Adapted from (Fernández-Formoso, Pérez-Sieira, González-
Touceda, Dieguez, & Tovar, 2015)  
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Leptin treatment regulates glucose utilization and determines blood glucose and 
insulin levels in ob/ob mice (Kamohara et al., 1997). Long and short term leptin treatment 
increases the glucose transporter GLUT4 expression and increases glucose uptake in BAT, 
but decreased levels of GLUT4 and glucose uptake in WAT. In muscle tissue, leptin 
decreases glycogen synthesis, increases fatty acid oxidation, and decreases fatty acid 
incorporation into triacylglycerol (Muoio et al., 1997). Leptin also regulates insulin-
sensitive peripheral tissues, pancreatic endocrine function, and CNS function.  Regarding 
carbohydrate metabolism, chronic leptin treatment increases insulin sensitivity of liver 
tissue and increases glycogen synthesis (Harris, 1998). 
 During leptin treatment, uncoupling protein expression increases so that when food 
intake is reduced, energy expenditure does not also decrease  (Baile et al., 2000).  When 
UCP is activated, ATP synthesis is uncoupled from oxygen consumption in mitochondria.  
Long term administration of leptin increased UCP1 and UCP2 expression in BAT and 
WAT, and UCP3 expression in BAT and skeletal muscle (Commins et al., 1999). The 
metabolism of glucose is responsible for the negative energy balance associated with leptin 
treatment (Kamohara et al., 1997). As such, leptin prefers energy-dissipating mechanisms: 
UCP1, UCP2, and UCP3 (Cusin et al., 1998).  
 Leptin increases the rate of lipolysis in white adipocytes from Zucker lean (fa/fa) 
rats (Siegrist-Kaiser et al., 1997). In mice treated with leptin, expression of lipase, the 
primary regulatory enzyme in the lipolytic pathway, increases in WAT, but not in BAT 
(Sarmiento et al., 1997). CART is released onto adipocytes to increase lipolysis (Wang et 
al., 1999). Leptin was found to inhibit expression of acetyl coenzyme A-carboxylase, 
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which is the major rate-limiting enzyme in lipid acid synthesis, and fatty acid synthase, 
which catalyzes the final reaction in fatty acid biosynthesis.  Together these pathways block 
fatty acid synthesis and increase both mitochondrial fatty acid oxidation and uptake.  
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Effect of Leptin Treatment 
Animal Studies 
Leptin Resistance  
Three sequential steps can be distinguished in the development of leptin resistance 
in mice models (Lin et al., 2000).  The first is that there is an increase in the amount of fat 
mass following feeding of a high fat composition meal, even though mice still respond to 
peripheral exogenous leptin treatment and are able to restrict their food consumption.  The 
second step consists in the beginning of the onset of peripheral leptin resistance when 
leptin’s effects are seen outside the CNS. This is the stage before central resistance where 
lack of downstream STAT3 phosphorylation is evidenced following leptin central injection 
through the BBB into the hypothalamus (some regions of the hypothalamus do not have a 
BBB. You should check your sources).  This progression helps explain the development of 
leptin resistance caused by the introduction of high fat diet. Hence, increasing adiposity 
propagates leptin resistance.  
Researchers have elucidated six different strategies to treat the problem of leptin 
resistance: restriction of calories and general exercise, reversal of the inhibition caused by 
SOCS3 and PTP1B, activation of POMC neurons, cell surface localization and leptin 
receptor expression, increase efficiency of transport through the BBB, and reduction of ER 
stress (Santoro et al., 2015). Down regulation of SOCS3 and PTP1B expression  promotes 
leptin signaling, since they are both negative regulators. POMC activation induces alpha-
MSH-mediated suppression of food intake, with an accompanying increase in energy 
expenditure (Hill, 2010). Modifications to leptin, such as the conjugation of leptin with a 
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carbohydrate moiety, of leptin showed improvements of transport through the BBB and 
influence total energy balance (Kovalszky et al., 2010).  Other types of modifications with 
transactivating transcriptional activator or with PluronicR, were efficient in overcoming 
general leptin resistance (Price et al., 2010). Together, these strategies have been shown to 
be effective starting points when trying to understand how to utilize exogenous leptin. 
 
Treatment Strategies through the Leptin System 
The first therapeutic treatment would be to administer exogenous leptin to leptin 
deficient subjects. Researchers hypothesized that a small portion of obese individuals (5-
10%) who naturally have low endogenous levels of leptin would be completely sensitive 
to exogenous leptin treatment (Ioffe et al., 1998). Obese transgenic mice that under secrete 
leptin and undertake leptin treatment undergo a subsequent restoration of metabolic 
function that were initially caused by the leptin deficiency. The researchers mated animals 
carrying an aP2-human leptin transgene with C57BL/6J ob/ob mice and found significant 
weight loss. Naturally occurring low plasma leptin concentrations can therefore be 
corrected simply with administration of high doses of exogenous leptin. Regarding this 
correction, leptin is able to effectively reduce body weight and correct metabolic 
abnormalities normally associated with obesity.  
Daily intraperitoneal injections on mice with a mutated ob gene with recombinant 
leptin protein lowered the percentage of body fat, body weight, food consumption, and 
circulating concentrations of both insulin and glucose (Pelleymounter et al., 1995).  The 
recombinant leptin protein normalized metabolic status, with parameters set by activity 
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levels, body temperature, and metabolic rate to levels similar to those of lean controls. In 
addition, after two weeks of daily intraperitoneal injections of both mouse or human 
recombinant leptin protein, ob/ob mice reduced body weight by 30% (Halaas et al., 1995). 
These results were milder in wild-type mice as injections twice daily resulted in a 12% 
body weight loss, markedly lowered food intake, and reduction of body fat from 12.2% to 
0.7%. In both the ob/ob and wild-type mice, exogenous leptin caused weight loss only 
observed in the adipose tissue. These results show the efficiency of using recombinant 
leptin protein to reduce weight in wild-type mice and that human recombinant leptin 
protein could be used successfully in mice. 
Researchers synthesized Fc-leptin immunofuscins (a Fc fragment of an 
immunoglobulin gamma chain attached to the leptin gene) which had enhanced 
pharmacological properties compared to simple recombinant leptin and lowered body 
weight significantly (Lo et al., 2005). In addition, Fc-leptin displayed a prolonged 
circulating half-life of several hours compared to a few minutes for recombinant leptin.  A 
treatment schedule of 0.25 mg/kg three times a week or 1 mg/kg once every 4 days was 
created. After one year, ob/ob mice that were injected daily were healthy and fertile, with 
decreased appetite and normalized blood glucose levels. These results indicate that Fc-
leptin is a good candidate for the treatment of non-leptin deficient obese humans as clinical 
efficacy is established.   
Researchers also created an allosteric monoclonal antibody XPA.80.037 that 
activates the leptin receptor and has both a prolonged half-life and low immunogenicity 
(Bhaskar et al., 2016). The treatment of ob/ob mice with XPA.80.037 corrected many of 
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the metabolic effects associated with leptin deficiency; they exhibited reduced appetite and 
body weight, corrected dyslipidemia, and normalized blood glucose and plasma insulin 
levels.  Because these changes correlated with modifications in mRNA levels of NPY and 
POMC, XPA.80.037 was determined to be effective in affecting the entire hypothalamic 
system and the related downstream leptin signaling pathways.   
 Using gene therapy to overexpress leptin in the rat hypothalamus, researchers 
prevented the weight gain usually associated with that seen with increasing age (Dhillon et 
al., 2001).  In this experiment, researchers used a recombinant adeno-associated virus 
vector, which encoded the rat leptin cDNA. As a result of this treatment, there were 
markedly reduced white fat depots and an increase in UCP-1 mRNA expression in BAT, a 
process which increases energy expenditure through the process of thermogenesis. Because 
of this pathway, leptin gene delivery into the hypothalamus is a sustainable therapeutic 
strategy to control the problem of age-related weight gain and provide protection from both 
hyperleptinemia (higher than normal amount of plasma leptin) and hyperinsulinemia 
(higher than normal amount of plasma insulin).   
 
Combination Treatments 
Researchers searched mRNA expression profiles for a leptin sensitizer and 
identified Withaferin A (J. Lee et al., 2016).  Treatment of DIO mice with Withaferin A 
before leptin treatment resulted in a 20-25% decrease in body weight, while also reducing 
metabolic abnormalities caused by obesity. Another researcher confirmed this 
effectiveness as treatment of leptin-resistant DIO mice with Withaferin A before leptin 
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treatment for 21 days reduced body weight by 23%, decreased food intake by 62%, 
significantly lowered circulating leptin concentrations, and lowered fat mass by 35% 
compared to controls (Crunkhorn, 2016). Leptin had few clinical effects in DIO mice, but 
pretreatment of these mice with Withaferin A sensitized them to leptin’s effects, resulted 
in a greater decrease in body weight and food consumption compared to mice receiving 
Withaferin A treatment alone.  
Co-administration of weight-loss inducing hormones, in addition to leptin, restored 
leptin responsiveness in DIO mice. In rodents, the co-administration of exendin-4 and 
fibroblast growth factor (FGF)-21 enhances leptin sensitivity and restores responsiveness 
to leptin in DIO mice, after an initial 30% decrease in body weight (Müller et al., 2012). 
Another weight-reducing agent, sibutramine, also enhanced the effects of leptin (Boozer et 
al., 2001).  Sibutramine is an anorexigenic agent that decreases energy expenditure and 
increases the feeling of hunger. Researchers tested if leptin enhanced the intercurrent 
efficacy of sibutramine. In this forty male Sprague-Dawley rats study, replacement doses 
of leptin with sibutramine administration increased fractional fat loss and weight loss by 
inhibiting food intake and stimulating fat oxidation. These combinations with other weight-
lowering agents are additively efficacious and proven to show success in enhancing leptin 
treatment. 
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Human Studies 
Leptin Resistance  
A relatively new hypothesis to explain leptin resistance is that stress to the 
endoplasmic reticulum plays a key role in the progression of leptin resistance (Hosoi et al., 
2016). The four basic mechanisms of leptin resistance are shown in Figure 5 (Hosoi et al., 
2016). Too much intake of bulky saturated fatty acids causes ER stress. Fluvoxamine, a 
serotonin reuptake inhibitor, improves the deficits caused by ER stress and inhibits obesity 
by reducing leptin resistance in neuronal cells. Also, chemical compounds that assist in 
protein folding, such as 4-phenyl butyric acid (4-PBA) have been found to reduce ER 
stress.  
 
Figure 5 - Mechanism for Developing of Leptin Resistance with Obesity. Adapted from 
(Hosoi & Ozawa, 2016). 
  
 
In patients with improper leptin signaling, four approaches are currently used to 
stop leptin signaling: using leptin antagonistic mutants, leptin and leptin receptor specific 
	37 
(monoclonal) antibodies or nanobodies, leptin peptide antagonists, and soluble leptin 
receptor variants (Zabeau et al., 2015). The first leptin antagonists designed by Verploegan 
et al. showed that human leptin R128Q blocks leptin activity and resulted in weight gain 
and high concentrations of insulin (Verploegen et al., 1997). This substitution of human 
leptin did not affect the binding with the receptor, but knocked out its biological activity. 
Leptin peptide modulators also act as potent leptin agonists and OBGRP (obesity gene 
related peptide) 22-56 was designed by Samson et al. to inhibit food intake and weight loss 
(Samson et al., 1996).  The results showed that a small, readily synthesized fragment of 
leptin, as seen with the 35 amino acids primary sequence from 22 to 56, exerts its satiety 
effects on the hypothalamus.  
 
Treatment Forms of Leptin 
Comparable weight loss was seen in a study with 54 lean and 73 obese humans who 
had low to normal leptin concentrations (Heymsfield et al., 1999). With recombinant 
methionyl human leptin injections, the higher the doses, the greater the fat loss in patients. 
In this study, researchers also did not observe any clinically significant adverse effects on 
other major organ systems, suggesting that this standard route of treatment does not have 
any noticeable negative side-effects. 
Exogenous leptin administration, even at very high doses, does not cause body 
weight decrease, except leptin deficient obese subjects (Blüher et al., 2009). However, r-
metHuLeptin replacement has shown therapeutic efficacy in restoring neuroendocrine, 
metabolic, and immune functions in children with congenital or acquired lipodystrophy.
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 In 2014, the US Food and Drug Administration approved AstraZeneca’s Mylapt to 
treat generalized lipodystrophy, a disease that causes the patient to have defective adipose 
tissues (Sinha, 2014). With abnormal adipose tissue, individuals would not be able to 
secrete leptin, since it is an adipokine, and individuals therefore eat nonstop. Mylapt is a 
recombinant form of the human leptin and was able to decrease hemoglobin A1c levels, a 
parameter of blood glucose levels, from an average of 8.7 to 6.7 in a study of 58 patients 
with congenital or acquired generalized lipodystropy. 
Persons with congenital lipoatrophy have hypoleptinemia; treatment with 
recombinant human leptin counters insulin resistance, lowers hemoglobin A1c levels by 
about 3.5%, reverses hepatic steatosis, suppresses hepatic gluconeogenesis, and improves 
hyperlipidemia (Rosenbaum et al., 2005; Javor et al., 2005; Oral et al., 2002). Leptin is 
available for congenital lipoatrophy through a US Food and Drug Administration approved 
expanded access program.    
Medical intervention with recombinant human leptin therapy on a nine-year old 
patient who had congenital leptin deficiency led to reversing fat gain (Farooqi et al., 1999).  
Because of the treatment, this patient lost approximately 400 kcal/day; the main reason 
being that the patient substantially lowered food consumption. However, the patient’s 
reduction in basal metabolic rate was counterbalanced by an increase in the patient’s energy 
expenditure, which was attributed to physical activity. Changing the BMR was the target 
for leptin’s effects. As we discussed previously, BMR is one of the largest component of 
calorie usage by the human body; serum leptin level is a strong indicator of the resting 
metabolic rate (RMR) in healthy individuals  (Jørgensen et al., 1998). Humans with 
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congenital complete leptin deficiency respond to recombinant human leptin treatment 
(Farooqi et al., 1999). Amylin Pharmaceuticals (San Diego, California) provides 
exogenous leptin for congenital leptin deficiency.   Amylin also found that when combined 
with pramlintude, overweight and obese subjects had better results (Ravussin et al., 2009). 
In a study of 13 Pakistani subjects who had a mutation in the leptin gene causing it 
to be dysfunctional, the serum leptin concentrations were abnormally low (Farooqi et al., 
2001). Serum level was positively correlated with indices of adiposity and BMI, correlation 
coefficient = 0.54. Exogenous leptin treatment in these patients resulted in decreased 
appetite, increased weight loss, increased physical activity, changed endocrine function 
and metabolism, and improved ingestive and noningestive behavior.  Leptin must be 
monitored by a homeostatic feedback system that coordinates fat mass increases with 
restoring leptin levels to normal concentrations.  
After 12 weeks of reducing fat consumption, leptin treatment in humans contributes 
to ongoing weight loss (Weigle et al., 2003).  In general, caloric restriction decreases leptin 
levels, increases ghrelin levels, and increases appetite since the body feels hungry. 
However, dietary fat restriction decreases adiposity without the accompanying increases in 
appetite leading to successful weight loss strategies.  The researchers found that weight 
loss early in the early course of the diet does not depend on the increase in plasma leptin 
levels. It is the later increase in strength of the long term leptin signal that contributes to 
keeping the weight loss. Leptin treatment causes neuroendocrine, metabolic, and 
autonomic responses that cause compensatory weight gain. The reduced leptin levels that 
occurs during general weight loss activates neuroendocrine response mechanisms that react 
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and tries to make subjects regain the weight they had previously shed. Weight regain might 
be achievable with leptin treatment, through reversing leptin deficient physiological state. 
Table 4 shows other common leptin deficient states (Kelesidis et al., 2010). 
 
Table 4- Leptin Deficient States. Adapted from (Kelesidis et al., 2010). 
 
 Treatment with a pegylated form of human leptin failed to achieve clinical efficacy 
(Hukshorn et al., 2000). 30 obese men had weekly subcutaneous injections of 30 mg 
pegylated leptin or placebo for 12 weeks. There were no significant changes in weight loss 
%, body fat %, or sleeping metabolic rate. However, there was a large reduction in serum 
triglycerides, which suggests that this form of treatment may have biological effects in 
tracking obesity, but not enough to be a weight reducing agent  
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Combination Treatments  
Researchers have used creative means to try to attack obesity using leptin inhibitors 
from fungal endophytes, which are microbes that live in symbiosis with plants ( (Mouli et 
al., 2016). The researchers hypothesized that they could reverse leptin resistance by using 
anti-leptin receptor saponins compounds, which modulates the immune system, followed 
by administration of recombinant leptin.  Leptin receptor neutralization with saponin 
compounds could desensitize the leptin receptor.  Obesity can be caused by immune system 
inflammation which leads to elevated leptin levels. LIFE (leptin inhibitors from fungal 
endophytes) is used as immune therapy and have immune modulating properties via the 
NF-kB pathway. 
   
 
 
 
 
 
 
 
 
 
 
	42 
Discussion 
 
Animal and Human Studies  
At first, the discovery of leptin excited scientists and led to hopes that it could be 
used as some sort of ‘magic bullet’ to treat human obesity, since it was one of the major 
hormones in charge of regulating human appetite. Researchers wanted to see if they could 
use this signaling pathway to tell the body to stop eating. Over time and through many 
experiments, the leptin treatment approach to obesity turned out to be more complicated 
and not a miraculous weight loss option. However, the discovery of leptin and the 
thousands of papers published on the subject have indeed provided new insights into 
weight control and adipocytes’ function (Wilding, 2002). There is a significant contrast 
between leptin treatment efficiency and efficacy in animals and humans, due to the 
obvious anatomical, physiological, and genetic differences. 
 One of the main concerns regarding obesity is the development of leptin 
resistance in obese subjects.  As individuals are not able to receive the leptin signaling to 
stop eating, hyperphagia causes them to become morbidly obese. Because the 
mechanisms and stages of developing leptin resistance are well established and 
elucidated out, the problem of leptin resistance can now be targeted quickly (Lin et. al., 
2000) To this extent, Santoro et al.’ six strategies have been well tested and confirmed to 
be viable options to develop medical treatments to overcome leptin resistance (Santoro et 
al., 2015). The main form of leptin resistance is largely occurring at the central level of 
the hypothalamus and its peripheral actions on other body sites have less control over 
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appetite.  Problems with transport through the BBB or of activating the hypothalamic 
leptin receptor have led to different strategies from improving BBB transport to 
activating downstream products. Peripheral leptin resistance is less studied and 
documented and does not seem to be as important because leptin’s main actions are on 
the hypothalamus. General leptin resistance is the answer why simple exogenous leptin 
treatment is not able to be used as a weight reducing medical treatment for obese subjects 
who have non-leptin deficient diseases.   
As compared to animals, the efficacy of exogenous leptin treatment in humans is 
less established.  However, leptin treatment is very effective for some specific diseases. 
For instance, patients with congenital complete leptin deficiency can be treated with 
exogenous leptin treatment, which has been shown to do its main job of lowering body 
weight and reducing appetite (Farooqi et al., 1999).  In these individuals, the lack of 
leptin can just be restored, since none of the signaling pathways are damaged.  However, 
these individuals would have to have exogenous administration of leptin throughout their 
lives, as their bodies are unable to produce it. A subset of the population (5-10%) of 
obese individuals who have naturally low plasma leptin concentrations can be cured 
simply with exogenous leptin treatment (Ioffe et al., 1998). So, instead of fixing the 
defect, clinicians supply the necessary stimulus to achieve the same effect. As also seen 
with Farooqi et al.’s experiment, patients who are partially leptin deficient can see 
positive clinical results from exogenous leptin treatment; however, this approach has its 
limits (Farooqi et al., 1999).   
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Modifications and improvements to leptin structure are well established and 
clinically effective in treating many diseases caused by leptin deficiency. Pelleymounter 
et al. showed that a recombinant leptin protein form could be used to help correct the 
endocrine and metabolic abnormalities usually associated with leptin deficiency 
(Pelleymounter et al., 1995). So instead of just fixing the leptin signaling pathway, 
medical treatment could fix the previous damage done to other organ systems by leptin 
deficiency. Lo et. al documented pre-clinical efficacy with a superior form of leptin, a Fc-
leptin immunofusin and established a dosing schedule. By manipulating the structure of 
leptin and adding a component of the immunoglobulin chain helped the leptin treatment 
last longer in plasma and therefore requiring fewer treatment doses, which is clinically 
beneficial. Design of different forms of leptin to be used in treatment is one of the easiest 
ways to tackle leptin-related causes of obesity, as exogenous administration of modified 
leptin would restore leptin’ signaling pathways.  
Generally, leptin combination treatment with either a sensitizer or a weight 
reducing agent helped the efficiency when compared with just using leptin treatment 
alone (Lee et al., 2016). This is generally due to the effect of first sensitizing the leptin 
receptor to leptin before actually applying leptin. The effect of activating leptin signaling 
is greater due to the lower concentration of leptin that is needed to activate the receptor. 
Finding the most efficient combination and at the same time limiting the cross actions 
between the two components would create the optimal leptin treatment. This synergistic 
effect enhances the ability of leptin to do its main job of causing obese subjects to lose 
weight by inhibiting appetite. We see the common theme that the leptin gene needs to be 
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combined with another molecule to have greater efficiency in establishing efficacy, 
especially in patients who have non-leptin deficient diseases. 
Researchers have also studied the results of leptin treatment and the common 
phenomena of regaining the lost weight post-leptin treatment (Weigle et al., 2003).  As 
discussed previously, the human appetite is a multi-faceted system that is regulated at 
many different systematic levels, with different systems acting and impacting each other.  
Researchers have found human adaptations to leptin treatment in the form of 
neuroendocrine mechanisms that reversed the feeling of satiety, and therefore subjects 
felt hungrier after treatment (Rosenbaum et al., 2005). This is a problem because it limits 
the gains achieved by leptin treatment. As such, simple caloric restriction or exercise 
increased ghrelin and appetite levels. Researchers have to take this into account when 
designing a medical treatment regimen that will account for inadvertent weight gain 
caused by regulatory feedback from the body. The body has homeostatic mechanisms 
that bring changes to the norm, so leptin treatment has to be prolonged so that the body 
can adapt by controlling hunger to the new nutritional state.  
 
Future Research Areas 
 Leptin dysregulation leads to many medical problems mainly concerning obesity 
and type 2 diabetes, but it also can also lead to cardiovascular and endocrine related 
diseases.  The interplay of leptin intervention with other treatments used to handle these 
diseases can be explored by researchers to see whether leptin treatment can unknowingly 
cause unwanted side effects in these systems. Researchers also can explore if there is a 
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synergistic or antagonistic effect when treatments are combined and when there are 
different cellular targets. Leptin’s main actions are on regulating appetite, but it has 
multiple pathways that can be seen as unrelated to obesity such as bone health and 
reproduction. Therefore, further knowledge of leptin deficiency’s effect on other organs 
is worth exploring. 
 Researchers can also compare the effects of leptin with its counterpart, ghrelin, 
which is an orexigenic hormone increasing appetite.  Ghrelin signaling pathways can be 
studied further and see if there is crosstalk with leptin signaling pathways, since one 
should actively inhibit the other. Experiments with exogenous ghrelin treatment could 
have the same benefit on ghrelin-deficient patients as seen with exogenous leptin 
treatment on leptin deficit patients. In addition, ghrelin can be studied the same way 
leptin was studied, from determining ghrelin resistance to developing different forms of 
ghrelin, which should have improved efficacy in the clinical setting.  
 Central leptin resistance is of vital importance and should be further researched. 
Because leptin works in the arcuate nucleus of the hypothalamus, finding analogs of 
leptin that can efficiently pass through the BBB would be an effective approach to 
maximize leptin’s potential.  By developing and testing different forms of leptin, 
researchers can choose the most effective one to saturate the leptin receptor and cause 
downstream signaling. However, because of the multitude of different forms of leptin that 
have been created and used in medical treatments, a clinical trial should be conducted in 
which all the popular and available forms are compared and one modified form of leptin 
becomes the golden standard for patients with leptin deficiency. Also, researchers can 
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optimize leptin sensitizers and weight reducing combinations and compare their 
efficiency plus possible side effects to see which treatment program health professionals 
should recommend to their patients.   
Targets of leptin pathways and downstream products are also effective in 
modulating the effects of leptin.  Instead of focusing on leptin activating the leptin 
receptor, researchers can also amplify downstream products and signals to get the desired 
response. Since the leptin pathway can be activated at multiple sites, leptin’s general 
effects of being an anorexigenic hormone can be achieved without the use of exogenous 
leptin. Further research and development targeting these by and end products would be 
the same as solving the problem of leptin not activating its receptor. However, because 
these products are also involved in different pathways, this approach would have to take 
into consideration the possible side reactions and ensure proper targeting for intended 
effects.   
 Leptin treatment, in general, is effective for patients with partial to complete 
leptin deficiency.  It has well documented effects of raising plasma leptin concentrations, 
correcting endocrine and metabolic abnormalities, and inhibiting the feeling of hunger. 
Leptin plays an essential role in the regulation of appetite, and further research should 
expand on the current knowledge of leptin in general and the possibility that leptin can 
someday be used a general weight-loss treatment. By investigating further and 
discovering new facts about leptin as related to obesity, public health officials and 
researchers can solve the obesity epidemic, one pathway at a time.  
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